Search results
Showing 1 to 7 of 7 results for anakinra
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
etanercept and infliximab 4 April 2007 TA072 Rheumatoid arthritis - anakinra 18 September 2003 TA375 Rheumatoid arthritis - adalimumab,...
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)
This appraisal has been updated and replaced by NICE guideline CG79.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.